Business Wire

ECHODYNE

15.4.2024 09:01:30 CEST | Business Wire | Press release

Share
Counter UAS Technology Europe 2024: Echodyne to Address Key C-UAS Conference Amidst Rapid Expansion into European Market

Echodyne, the radar platform company, is excited to announce it will be addressing the second annual Counter UAS Technology Europe 2024 conference, taking place at the Marriott Hotel Grosvenor Square in London over April 16-17, 2024. Echodyne VP of Marketing, Leo McCloskey, will discuss important counter-UAS developments in accuracy and mobility. Echodyne’s participation in this year’s event comes on the heels of significantly expanding its footprint in the region with new, European-based team members.

The conference is hosted by SAE Media Group and focuses on gathering European C-UAS stakeholders to address the growing proliferation of small drones and unmanned aircraft system (UAS) technology and the need for European armed forces and security agencies to protect critical national infrastructure and personnel at home and abroad by way of cutting-edge, C-UAS operations.

Drones are an increasing threat beyond the battlefield with payload and operational capabilities that challenge existing sensors and systems. From low, slow, and very effective small UAS to larger Group 3 UAS, the threat to logistics, missions, and warfighters is vast and expanding. Part of the challenge is sensors that can accurately track and deliver precise airspace coordinates of the intruding UAS, for which Echodyne’s metamaterials electronically scanned array (MESA®) are uniquely capable.

Cost symmetry is another challenge, with non-state actors spending small amounts on UAS weapons that require multi-million dollar systems to defeat. Echodyne’s radars achieve the optimal balance of low-cost, commercial off-the-shelf (COTS) advanced technology and high-performance, active beamforming ESA precision to create the most powerful, low-SWaP radars on the market. With both processed and unprocessed data integration options, Echodyne radars generate the most accurate data for detecting, tracking, targeting, and mitigating UAS threats.

“Solving the ‘drone problem’ requires technology and software that, when integrated, contributes high-fidelity, actionable data from attritable COTS platforms,” said Todd Fraser, Chief Revenue Officer at Echodyne. “Customer requirements are rapidly and radically changing, from fixed and portable to highly mobile, from crewed to uncrewed to platforms, from range as the sole driver to greater emphasis on spatial accuracy. Echodyne is expanding to meet increasing customer demand across Europe, Middle East, and Africa for low SWaP, commercially-exportable radars with superior ESA performance.”

Those interested in learning more about Echodyne’s radar for C-UAS operations, including remote weapons stations (RWS), short-range air defense (SHORAD) programs, and more are invited to attend Echodyne’s session at the Counter UAS Technology Europe 2024 Conference at 11 am BST on April 16, 2024. Those who are unable to attend can connect directly with a member of the Echodyne team here.

About Echodyne

Echodyne, the radar platform company, is a U.S. designer and manufacturer of advanced radar solutions for defense, government, and commercial market applications. The company’s proprietary metamaterials electronically scanned array (MESA®) architecture is a rare breakthrough in advanced radar engineering. Echodyne’s innovative MESA radars use standard materials and manufacturing processes to shatter unit cost barriers for high performance radar. The result is a solid-state, low-SWaP, exportable, commercial radar with advanced software capabilities that delivers superior performance, unparalleled data integrity, and exceptional situational awareness. Privately held, the company is backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, Northrop Grumman, and Supernal, among others. For more information, please visit: Echodyne.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415117922/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye